AstraZeneca’s Post

Early diagnosis using screening programs is crucial to improve the survival rate in lung cancer.

While a lung cancer diagnosis is never easy, personalized treatment options can offer a beacon of hope.   As research continues to advance, our focus on scientific excellence and innovation is driven by our ambition to help transform the lives of patients everywhere; we’ve dedicated our world-class research capabilities to drive forward more breakthroughs for treating this disease.   On this World Lung Cancer Day, we celebrate the progress that we've made while recognizing there is still more work to be done. Together, we can pave the way for a future where lung cancer is manageable.   In case you missed it, I recently described this precision approach for non-small cell lung cancer in Endpoints News earlier this year. If you’re interested, you can read it here: https://bit.ly/3ymSs4E   #WorldLungCancerDay #LungCancerAwareness #JNJOncology #WLCD24

Cancer Information Revolutionized: American Cancer Society and American Society of Clinical Oncology (ASCO) Unite to Create Comprehensive Online Resource The American Cancer Society and the American Society of Clinical Oncology (ASCO) have announced a partnership to create one of the largest and most comprehensive online sources of cancer information, accessible for free on cancer.org. This collaboration revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, aims to merge American Cancer Society’s patient education resources with American Society of Clinical Oncology (ASCO)’s expertise in cancer care. It supports the Biden Cancer Moonshot’s goals of reducing cancer mortality and improving patient experiences. This effort is endorsed by key figures like American Cancer Society CEO Karen E. Knudsen, American Society of Clinical Oncology (ASCO) CEO Clifford A. Hudis, and Dr. Danielle Carnival of the Biden Cancer Moonshot. The National Cancer Institute (NCI) also praised the partnership for its potential to offer reliable, timely information amidst the rapid pace of scientific advancement and the proliferation of misleading online content. For more details please click the link! https://lnkd.in/gpqFPN6C #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

When it comes to lung cancer treatment, understanding patient preferences is crucial. We’ve worked with Dr. Kenneth Culver MD from ALK Positive Inc., Pfizer, and other leading experts to explore what patients in the UK and US prioritise when making treatment decisions for ALK lung cancer. Our study highlights the importance of focusing on what truly matters to patients - like overall survival, quality of life, and the ability to prevent the spread of cancer. We found that even small differences in patient experiences can significantly influence treatment choices. This collaborative work featured at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (WCLC) in San Diego, as part of the Patient Advocacy - Clinical Communications session. #ALKPositive #WCLC24 #NSCLC #TargetedTherapy #LungCancer

We all have the power to reduce the impact of cancer – for ourselves, the people we love, and the world. The key is taking action. Today is World Cancer Day, a great reminder that small actions, taken by many people, can add up to help the millions of people affected by cancer around the world. With the motto #CloseTheCareGap, World Cancer Day is also about improving access to cancer treatments. At Novocure, we strive to bring our innovative therapy to as many patients as possible that may benefit from it: 1. In our clinical studies, we research the efficacy and safety of our therapy in some of the most aggressive forms of cancer. 2. We work with legislators to ensure that innovative medical therapies become available to patients faster. Let’s continue to work together to close the care gap. If you have an idea, get in touch with us. https://lnkd.in/gsRaWQ-9 And let’s all take one action today to help a cancer patient we know on #WorldCancerDay. #oncology #medtech #CloseTheCareGap #patientforward

Everyone in the world, regardless of age, background, or income, has been impacted by cancer. Today, we are reminded that while significant progress has been made, our battle with this unrelenting disease is far from over. At Novocure, our unique #patientforward approach has always played a central role in driving our mission of extending survival in some of the most aggressive forms of cancer, a destructive disease that has affected so many individuals and families across the globe. Despite revolutionary advancements in the development of innovative cancer therapies – like Tumor Treating Fields – current reimbursement policies continue to be hurdles for patients who would benefit the most from these types of treatments. On #WorldCancerDay it is crucial that we reflect on the importance of closing these gaps in healthcare so that cancer patients everywhere have unrestricted and timely access to the most innovative cancer treatments on the market. 

Today is World Lung Cancer Day. This is an annual observance designed to commemorate those who are impacted by lung cancer and raise awareness about lung cancer. Listen to Claire's story which highlights how screening led to early detection and successful treatment of her lung cancer at Regional Hospital of Scranton. Lung screening has the potential to detect lung cancer at earlier stages when it has the best chance of being treated. Commonwealth Health Imaging screens high-risk patients for lung cancer at multiple locations using low-dose CT- https://lnkd.in/dxGMEF-Q

Today, on Cancer Survivors Day, and throughout June, Cancer Survivors Month, we honor the courage, resilience, and strength of those who have navigated the cancer journey. This year we mark these occasions by sharing groundbreaking research at #ASCO2024. Our latest studies, on lung cancer patients, investigated the efficacy of personalized drug regimens based on the analysis of 600 genes. The results were nothing short of transformative, showing a 2.6-fold increase in overall survival and a 3-fold improvement in progression-free survival for patients treated according to Genomate's recommendations. These findings are not just numbers; they represent hope, more moments, and better quality of life for patients and their families. As we share these promising results with the global oncology community, we remain dedicated to delivering on the true promise of personalized oncology. We are proud to be contributing to a future where more patients can say, “I am a survivor.” #CancerSurvivorsDay #CancerSurvivorsMonth #CancerResearch #GenomateHealth

🌟 Charting the Course in Advanced Prostate Cancer Management: Your Invitation to APCCC 2024 🌟 The Advanced Prostate Cancer Consensus Conference (APCCC) is the epicentre of global collaboration, where experts convene to bring clarity to the most pressing questions in advanced prostate cancer management and treatment. This is your chance to be part of a transformative experience that directly impacts clinical practice. Dive into engaging discussions, gain consensus on complex clinical decisions, and be at the forefront of cutting-edge research. 🌐 Our panel of international experts is as diverse as it is knowledgeable and committed to driving consensus in the face of uncertainty. Check out our world map of panel members and see the breadth of knowledge they bring to the table! 📅 25-27 April 2024 Save your seat at the APCCC 2024 and be a part of the conversation that's shaping the future of clinical care in prostate cancer. Register now and connect with leaders in the field: https://apccc.org/ #APCCC24 #ProstateCancer #ClinicalConsensus #OncologyResearch #MedicalConference #HealthcareCollaboration #CancerCare